ASCO 2023: Neoadjuvant FOLFOX Noninferior to Standard Chemoradiotherapy in Locally Advanced Rectal Cancer
Omission of radiotherapy tied to improved outcomes in patients with rectal cancer eligible for sphincter-sparing surgery
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.